Last10K.com

Becton Dickinson Co (BDX) SEC Filing 10-Q Quarterly Report for the period ending Thursday, June 30, 2022

SEC Filings

BDX Quarterly Reports

Becton Dickinson Co

CIK: 10795 Ticker: BDX

Exhibit 99.1

1 Becton Drive
Franklin Lakes, NJ 07417
www.bd.com



imagea.jpg



Contacts:
Investors: Francesca DeMartino, SVP, Head of Investor Relations - 201-847-5743
Media: Troy Kirkpatrick, VP, Public Relations - 858-617-2361

BD REPORTS THIRD QUARTER FISCAL 2022 FINANCIAL RESULTS

Revenue from continuing operations of $4.6 billion increased 0.7% as reported and 3.8% on currency-neutral basis
Revenue from continuing operations driven by base revenue growth of 6.0% as reported, 9.3% currency-neutral
Worldwide COVID-only testing revenues of $76 million declined from $300 million in the prior year
GAAP diluted EPS from continuing operations of $1.28; adjusted diluted EPS from continuing operations of $2.66
Company raises full year revenue and EPS guidance

FRANKLIN LAKES, NJ (August 4, 2022)
- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its third quarter of fiscal year 2022, which ended June 30, 2022.

“Our BD2025 strategy continues to serve as our True North and has proven to be an effective, winning strategy as reflected in our continued strong performance, even amid a challenging macro environment,” said Tom Polen, chairman, CEO and president of BD. “Through our talented team's focused execution and commitment to our purpose, we are advancing our Grow-Simplify-Empower initiatives, innovation pipeline and capital deployment strategy, which are all contributing to profitable growth. Looking forward, we expect continued momentum and remain well-positioned to drive long-term growth and value for all stakeholders.”

Recent Business Highlights

BD continues to advance its innovation-driven growth strategy, tuck-in M&A, and ESG initiatives.
Acquired Parata Systems, entering high-growth pharmacy automation market segment by offering a comprehensive set of technologies across the care continuum, and furthering strategy to drive smart, connected care.
Acquired MedKeeper, a provider of modern, cloud-based pharmacy management applications, including connected pharmacy software to support the preparation of compounded medications.
Launched BD COR™ System in U.S. Fully automated, high-throughput infectious disease molecular diagnostic platform includes 510(k) cleared BD COR™ MX instrument that elevates standard of care for sexually transmitted infections.
Obtained CE mark for COVID-19 and Influenza A/B combination test for BD COR™ MX.
Launched CE marked BD MAX™ respiratory viral panel for COVID-19, Influenza A/B and Respiratory Syncytial Virus.
Page 1

The following information was filed by Becton Dickinson Co (BDX) on Thursday, August 4, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Becton Dickinson Co's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Becton Dickinson Co.

Continue

Assess how Becton Dickinson Co's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Becton Dickinson Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
M & A
Legal
Other
Filter Subcategory:
All
Earnings
Expense
Geography
Product
Income
Shares
Cash Flow
Other
Inside Becton Dickinson Co's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Cover Page
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Income
Condensed Consolidated Statements Of Income
Basis Of Presentation
Benefit Plans
Benefit Plans (Detail)
Benefit Plans (Tables)
Business Restructuring Charges
Business Restructuring Charges (Detail)
Business Restructuring Charges (Tables)
Contingencies
Contingencies (Detail)
Contingencies (Policies)
Debt
Debt (Detail)
Derivative Instruments And Hedging Activities
Derivative Instruments And Hedging Activities (Tables)
Derivative Instruments And Hedging Activities - Additional Information (Detail)
Derivative Instruments And Hedging Activities - Schedule Of Notional Amounts Of Outstanding Derivative Positions (Detail)
Derivative Instruments And Hedging Activities Disclosure - Gains (Losses) On Net Investment Hedges (Details)
Discontinued Operations - Assets And Liabilities Of Discontinued Operations (Details)
Discontinued Operations - Income From Discontinued Operations, Net Of Tax (Details)
Discontinued Operations And Disposal Groups
Discontinued Operations And Disposal Groups (Tables)
Discontinued Operations And Disposal Groups - Additional Information (Details)
Earnings Per Share
Earnings Per Share (Tables)
Earnings Per Share - Weighted Average Common Shares Used In Computations Of Basic And Diluted Earnings Per Share (Detail)
Financial Instruments And Fair Value Measurements
Financial Instruments And Fair Value Measurements (Tables)
Financial Instruments And Fair Value Measurements - Additional Information (Detail)
Financial Instruments And Fair Value Measurements - Cash And Equivalents And Restricted Cash (Details)
Financial Instruments And Fair Value Measurements - Schedule Of Fair Value, Assets And Liabilities Measured On Recurring Basis (Details)
Financial Instruments And Fair Value Measurements - Transfer Of Financial Assets Accounted For As Sales (Details)
Intangible Assets
Intangible Assets (Tables)
Intangible Assets - Additional Information (Detail)
Intangible Assets - Components Of Intangible Assets (Detail)
Intangible Assets - Reconciliation Of Goodwill By Business Segment (Detail)
Revenues
Revenues (Details)
Segment Data
Segment Data (Tables)
Segment Data - Additional Information (Detail)
Segment Data - Financial Information For Company's Segments (Detail)
Segment Data - Revenues By Geographic Areas (Detail)
Shareholders' Equity
Shareholders' Equity (Tables)
Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) - Components And Changes Of Accumulated Other Comprehensive Income (Loss) (Detail)
Shareholders' Equity - Changes In Certain Components Of Shareholders' Equity (Details)
Subsequent Events
Subsequent Events - Additional Information (Details)

Material Contracts, Statements, Certifications & more

Becton Dickinson Co provided additional information to their SEC Filing as exhibits

Ticker: BDX
CIK: 10795
Form Type: 10-Q Quarterly Report
Accession Number: 0000010795-22-000052
Submitted to the SEC: Thu Aug 04 2022 12:58:06 PM EST
Accepted by the SEC: Thu Aug 04 2022
Period: Thursday, June 30, 2022
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/bdx/0000010795-22-000052.htm